艾乐替尼治疗ALK阳性非小细胞肺癌的研究进展

Research progress of alectinib in the treatment of ALK-positive non-small cell lung cancer

摘要: 克唑替尼作为第一代间变性淋巴瘤激酶酪氨酸激酶抑制剂(anaplastic lymphoma kinase-tyrosine kinase inhibitors, ALKTKIs), 在间变性淋巴瘤激酶(ALK)阳性晚期非小细胞肺癌(non-small cell lung cancer, NSCLC)患者的治疗中有着举足轻重的地位, 但其和所有的TKI一样, 也不可避免地遇到了耐药的问题。于是第二代ALK-TKIs (艾乐替尼、色瑞替尼、布加替尼等)应运而生, 本文就其中的研究热点之一艾乐替尼治疗ALK阳性NSCLC的研究进展进行综述。

Abstract: Rizotinib is a first-generation anaplastic lymphoma kinase-tyrosine kinase inhibitor (ALK-TKI) and plays an important role in the treatment of ALK-positive advanced non-small cell lung cancer (NSCLC).However, as with other TKIs, resistance development cannot be avoided with crizotinib.This led to the development of second generation ALK-TKIs such as alectinib, ceritinib, and brigatinib. This article reviews the research progress on treatment of ALK-positive NSCLC with alectinib, which is one of the hotspots.